Jay Cecil

Mr. Cecil joined Valence Advantage Life Sciences in 2012. Previously, Mr. Cecil was a Managing Director at Caxton Advantage which he joined in 2006. Mr. Cecil has 15 years of experience in the life sciences industry. Prior to joining the Fund, he was a Vice President in the Life Sciences Investment Banking Group at Piper Jaffray. Before Piper Jaffray, Mr. Cecil worked within the Health Care Investment Banking Group at Montgomery Securities. During his years in life sciences banking, Mr. Cecil completed over 60 financing and acquisition transactions worth over $5.6 billion for a range of life science clients including Anesta, MGI Pharma, Biomarin Pharmaceuticals, Alexion Pharmaceuticals and ILEX Oncology. While at Caxton Advantage, Mr. Cecil played an active role in a number of new investments, including VIVUS, Corthera, Regado Biosciences and Anthera Pharmaceuticals. Mr. Cecil earned an MBA from The Wharton School, University of Pennsylvania and an MS in Biotechnology from the University of Pennsylvania with a concentration in Immunology. He graduated Phi Beta Kappa from Lehigh University with a degree in Economics. Mr. Cecil is currently a Board Observer at Caxton Advantage portfolio company, Regado Biosciences.

A. Rachel Leheny, Ph.D.

Eric W. Roberts

Scott Morenstein

Rob Ferraioli

Devon E. Coger